Literature DB >> 24686095

Nanotechnology in the treatment of inflammatory bowel diseases.

Angelo Viscido1, Annalisa Capannolo2, Giovanni Latella2, Renzo Caprilli3, Giuseppe Frieri2.   

Abstract

BACKGROUND AND AIMS: Treatment of inflammatory bowel diseases (IBD) is only aimed to block or inhibit the pathogenetic steps of the inflammatory cascade. Side effects of systemic therapies, poor targeting of orally administered topical drug and low adherence to prescription represent frequent therapeutic challenges. Recent observations suggest that nanotechnology could provide amazing advantage in this field since particles having dimension in the nanometer scale (nanoparticles) can modify pharmacokinetic step of biologic and conventional therapeutic agents with a better delivery of drugs within the intestinal inflammatory cells. The aim of this review was to provide the clinician with an insight into the potential role of nanotechnology in the treatment of IBD.
METHODS: A systematic search (PubMed) for experimental studies on the treatment of intestinal inflammation using nanotechnology for the delivery of drugs. RESULTS AND
CONCLUSIONS: The size of the pharmaceutical formulation is inversely related to specificity for inflammation. Nanoparticles can penetrate epithelial and inflammatory cells resulting in much higher, effective and long-acting concentrations than can be obtained using conventional delivery systems. From a practical point of view, this should lead to improvements in both efficacy and adherence to treatment, providing patients with the prospect of stable and prolonged remissions with reduced drug loadings. Reduced systemic side effects could also be expected.
Copyright © 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Compliance; Drug delivery;; Inflammatory bowel diseases;; Microparticles;; Nanoparticles;; Therapy;

Mesh:

Year:  2014        PMID: 24686095     DOI: 10.1016/j.crohns.2014.02.024

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  18 in total

1.  Do ginger-derived nanoparticles represent an attractive treatment strategy for inflammatory bowel diseases?

Authors:  Mingzhen Zhang; James F Collins; Didier Merlin
Journal:  Nanomedicine (Lond)       Date:  2016-11-04       Impact factor: 5.307

2.  Can naturally occurring nanoparticle-based targeted drug delivery effectively treat inflammatory bowel disease?

Authors:  Chunhua Yang; Didier Merlin
Journal:  Expert Opin Drug Deliv       Date:  2019-11-28       Impact factor: 6.648

Review 3.  Modulating the immune system through nanotechnology.

Authors:  Tamara G Dacoba; Ana Olivera; Dolores Torres; José Crecente-Campo; María José Alonso
Journal:  Semin Immunol       Date:  2017-10-09       Impact factor: 11.130

4.  GLP-1 nanomedicine alleviates gut inflammation.

Authors:  Arivarasu N Anbazhagan; Mentor Thaqi; Shubha Priyamvada; Dulari Jayawardena; Anoop Kumar; Tarunmeet Gujral; Ishita Chatterjee; Edurne Mugarza; Seema Saksena; Hayat Onyuksel; Pradeep K Dudeja
Journal:  Nanomedicine       Date:  2016-08-20       Impact factor: 5.307

5.  Dextran-Coated Cerium Oxide Nanoparticles: A Computed Tomography Contrast Agent for Imaging the Gastrointestinal Tract and Inflammatory Bowel Disease.

Authors:  Pratap C Naha; Jessica C Hsu; Johoon Kim; Shrey Shah; Mathilde Bouché; Salim Si-Mohamed; Derick N Rosario-Berrios; Philippe Douek; Maryam Hajfathalian; Parisa Yasini; Sanjay Singh; Mark A Rosen; Matthew A Morgan; David P Cormode
Journal:  ACS Nano       Date:  2020-07-28       Impact factor: 15.881

Review 6.  Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease.

Authors:  Hidetoshi Takedatsu; Keiichi Mitsuyama; Takuji Torimura
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

7.  Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in an in vivo model.

Authors:  Chiara Dianzani; Federica Foglietta; Benedetta Ferrara; Arianna Carolina Rosa; Elisabetta Muntoni; Paolo Gasco; Carlo Della Pepa; Roberto Canaparo; Loredana Serpe
Journal:  World J Gastroenterol       Date:  2017-06-21       Impact factor: 5.742

8.  Colon-targeted delivery of cyclosporine A using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis.

Authors:  Muhammad Naeem; Junhwan Bae; Murtada A Oshi; Min-Soo Kim; Hyung Ryong Moon; Bok Luel Lee; Eunok Im; Yunjin Jung; Jin-Wook Yoo
Journal:  Int J Nanomedicine       Date:  2018-02-28

Review 9.  Current Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease.

Authors:  Fengqian Chen; Qi Liu; Yang Xiong; Li Xu
Journal:  Int J Nanomedicine       Date:  2021-06-23

10.  Mesoporous silica microparticles gated with a bulky azo derivative for the controlled release of dyes/drugs in colon.

Authors:  Daniel Ferri; Pablo Gaviña; Margarita Parra; Ana M Costero; Jamal El Haskouri; Pedro Amorós; Virginia Merino; Adrián H Teruel; Félix Sancenón; Ramón Martínez-Máñez
Journal:  R Soc Open Sci       Date:  2018-08-15       Impact factor: 2.963

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.